National Pharmaceutical Council’s Post

In my role at the Family Heart Foundation, I am privileged to work with many amazing people at these 10 organizations - our CAC members who represent the leaders in the lipid space. They work across many functions (advocacy, commercial, medical affairs, development, government affairs) but are unified in their commitment to bring new, innovative lipid therapies to market to reduce the impact of cardiovascular disease on families around the world. I benefit personally from Pharma’s investment in innovation in the 1980s and 1990s as my statin keeps my LDL at 40mg/dl - in the “safe zone”. But statins are not an option or sufficient for everyone. Even in this golden age of lipid lowering therapies, still >70% of high-risk Americans are NOT achieving their LDL targets and there are no treatments currently available for the millions of people at risk with elevated Lp(a). Continued investment in innovation by the biopharmaceutical industry is vital, as is access to these innovative therapies.🙏🏻 #KnowLpa #KnowFH #LDL #LowerIsBetter #CardiovascularHealth

🧬 Breaking Down Silos in Rare Disease Research: A Call for Collaboration Fresh off an incredible HLTH USA 2024 in Las Vegas, the innovation momentum continues as Boston's healthcare ecosystem gathers for our next Insider event hosted by Alexion Pharmaceuticals, Inc. Pharmaceuticals. This event will focus on a critical challenge in rare disease research: data sharing. 💡 Why this Insider? When each rare disease affects only a fraction of the population, and our data sits in isolated silos, we're fighting with one hand tied behind our back. But what if we could change that? 📈 The power of federated data sharing isn't just about pooling numbers – it's about unlocking possibilities: - Faster breakthrough discoveries - More comprehensive patient insights - Accelerated treatment development - Enhanced understanding of disease progression Pre-competitive data sharing is possible and it's time for the rare disease community to take that leap. We're bringing together minds from biopharma, digital health, and beyond to tackle the technical, ethical, and legal challenges head-on. The message is clear: The future of rare disease research isn't in isolation – it's in collaboration. 🇺🇸 Calling our Boston-based members: Let's build on the energy and insights from HLTH and turn them into actionable strategies for rare disease research. The conversation continues here. Find out more on our platform: https://lnkd.in/eCwz-mBq. Apply to join, directly on the site or message me. #RareDiseases #Innovation #BostonBiotech #HLTH2024 #HLTHCommunity

🧬 After Vegas Success, HLTH Community Sets Sights on Boston! The momentum is unstoppable! Fresh from our Think Tank triumphs HLTH USA, the HLTH Community is heading east to Boston. Join us and Alexion Pharmaceuticals, Inc. as we unite the rare disease community for groundbreaking discussions. 🌟 In the world of rare diseases, data is as precious as the treatments we develop. But what happens when we break down silos and unite our knowledge? 🎤 Join leading experts as we explore: ✅ The power of federated data sharing in rare disease research ✅ Breaking down barriers between pharmaceutical companies ✅ Building frameworks for successful industry collaboration ✅ Learning from oncology's successful data-sharing models Join us in creating a future where collaboration accelerates breakthroughs. Together, we're stronger. 💪 Apply now 🔗 https://lnkd.in/eA-28mmS

We had a great time at the 2024 Pharma Pricing Innovation Conference hosted by EVERSANA in Basel, Switzerland. The event was full of informative sessions and valuable discussions about the future of pharma pricing strategies. A highlight was our CEO, Girisha Fernando, presenting his talk, “Can You Bust the Myth of Outcome-Based Agreements?”. Girisha led an engaging discussion on value-based healthcare solutions, addressing the challenges and misconceptions about outcome-based agreements (OBAs). He explained how OBAs can improve patient care and manage costs more effectively in the pharmaceutical industry. Some key points from his presentation included the widespread use of OBAs in countries like the US, Spain, and Italy. We also looked at different types of agreements, like fixed discounts and outcome guarantees, and explored where OBAs are making a big impact, such as in treatments for oncology, T2D, MS, and SMA. Thank you to everyone who joined us - it was a wonderful chance to connect and share insights. If you missed the event, get in touch with us today to learn more: lyfegen.com/demo. #PPIC24 #PharmaPricing #ValueBasedHealthcare #Eversana #PharmaInnovation #OutcomeBasedAgreements #HealthcareTransformation

As a leader in the biopharmaceutical industry, collaboration is at the heart of everything we do at Bristol Myers Squibb. We are committed to advancing scientific innovation in areas like oncology, hematology, immunology, cardiovascular diseases, and neuroscience. Through partnerships, we expand our expertise and accelerate the delivery of transformative medicines to patients. Why partner with us? 🤝 🔹 Over 60% of our development pipeline comes from external collaborations. 🔹 19 out of 22 of our best-selling medicines were born from partnerships. 🔹 Over 300+ partners worldwide trust us to bring innovative solutions to life. Together, we work with creativity, flexibility, and a shared commitment to improving patient lives. At Bristol Myers Squibb, we continue to push the boundaries of science to deliver meaningful outcomes to those who need it most. Let’s connect and explore how we can make a lasting impact together. 💬 #Biopharma #Partnerships #Innovation #Healthcare #BristolMyersSquibb #BusinessDevelopment #TransformativeMedicines

🌟 The orphan drug sector, once a rising star in the pharma industry, is facing challenges ahead! 🚀 Despite fierce competition and pricing pressures, the market for rare disease drugs is still on the rise. 💊📈 🔝 In 2028, brace yourself for the top 10 most valuable orphan drugs making waves with a whopping $57 billion! 💰 Leading the pack are Johnson & Johnson's Darzalex, Vertex's Trikafta, and Roche's Hemlibra. 🏆 Exciting new players like Incyte and Novartis' Jakafi, as well as J&J's Carvykti, are making their mark too. 🌟 And let's not forget about Amgen's game-changing move with the acquisition of Horizon Therapeutics! 🌟 💡 The future of rare disease treatments is evolving, and these key players are at the forefront of innovation and impact. 🌍💊 #PharmaIndustry #OrphanDrugs #Innovation #HealthcareRevolution

🌐 DelveInsight Business Research LLP's Comprehensive Report on the Peripheral Arterial Disease (#PAD) Market 🌐 Explore comprehensive report on the Peripheral Arterial Disease Market, offering deep insights into market trends, unmet needs, emerging therapies, and future opportunities. Stay ahead in understanding the evolving landscape of #PADTreatment strategies. The leading #PeripheralArteryDiseaseCompanies such as Novo Nordisk, Takeda, Mercator MedSystems, Inc., Beijing Northland Biotech. Co., Ltd., Ixaka Ltd, Humacyte, Inc., CARDIOVASCULAR BIOTHERAPEUTICS, Proteon Pharmaceuticals ReNeuron Group Plc, Alucent Biomedical, Athersys, ARCA Biopharma, Ambulero, Venturis Therapeutics, Inc. and others. 🔗 Click here to access the full report ! @ https://lnkd.in/dGhiDXZE #PeripheralArterialDisease #PADMarket #HealthcareInsights #DelveInsight #MarketAnalysis #EmergingTherapies

Hot of the Press! It’s been publications galore in the RAS world in 2024 and the past week has been no exception. Luckily enough, first and best-in-class therapies for CRC, pan-RAS approaches and non-canonical targets will be the hot topics filled with BRAND NEW DATA, exclusively at the 6th Annual RAS-Targeted Drug Development Summit (September 24 – 26, Boston, MA). Peers from Revolution Medicines, Amgen, Loxo@Lilly, Roche, GenFleet Therapeutics, Nested Therapeutics, Astellas Pharma, and 40+ more organizations are uniting to improve the standard of care for patients with unmet needs. Download the brochure now to see our topics of choice and find out how to join them: https://ter.li/8vhngl References: https://lnkd.in/eqznq5rM https://lnkd.in/eHYFStQE

We are delighted to announce that we will receive the second Re𝜏ain-related milestone payment of CHF 24.6 million under the agreement with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company.   The fact that this payment comes earlier than expected is very gratifying as it is based on the rapid rate of pre-screening in the potentially registrational Re𝜏ain Phase 2b clinical trial in preclinical Alzheimer’s disease.   The Re𝜏ain trial is testing the hypothesis that ACI-35.030 has a disease-modifying effect that can delay or prevent the onset of cognitive impairment in individuals with pre-symptomatic AD through inhibition of seeding and spreading of pathological Tau. https://lnkd.in/emF6SYEE #Alzheimers #activeimmunotherapy #precisionmedicine #prevention

# Only put off until tomorrow what you are willing to die having left undone ## Don't Miss Out on Cue Biopharma's Clinical Updates and Business Strategies! Invest in your Health Savings Account today! 💪💰 Cue Biopharma, a leading clinical-stage biopharmaceutical company specializing in therapeutic biologics for cancer and autoimmune diseases, is set to present its latest clinical updates and business strategies at the Piper Sandler Healthcare Conference on December 4, 2024. This unplugged fireside discussion will provide valuable insights into Cue Biopharma's advancements in the healthcare sector. With its focus on developing innovative treatments for critical medical conditions, Cue Biopharma holds significant potential for growth and investment opportunity. As an investor, it is crucial to stay up-to-date with the latest developments in this dynamic industry. Attending conferences like the Piper Sandler Healthcare Conference allows you to gain first-hand knowledge of the cutting-edge research, clinical trials, and strategic initiatives that could shape the future of healthcare. Maximize the potential of your Health Savings Account by investing in companies like Cue Biopharma that have the power to transform lives through groundbreaking therapies. By strategically allocating your HSA funds, you not only secure your family's future but also contribute to the advancement of healthcare and overall wellness. Don't let the Fear of Missing Out hold you back! Take action today and invest in your HSA to generate long-term financial growth while supporting the improvement of global health. 📈💼💊 #hsa #investing #healthcare #health #family #wellness